Skip to main content

Advertisement

SpringerLink
Log in

Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA). We have recruited 120 patients with RA with a high disease activity despite being treated with MTX (15 mg/week) or LEF (20 mg/die) for 3 months, without side effects. In each of these patients, therapy with either MTX or LEF was continued and randomly combined with an anti-TNF-alpha drug: etanercept, infliximab, or adalimumab. Patients were assessed at study entry and at 4, 12, and at 24 weeks. The efficacy endpoints included variations in the DAS28-ESR and the ACR20, ACR50, and ACR70 responses. At each visit, any side-effect was recorded. There were no statistically significant differences in the DAS28 variations and in the ACR responses between the two groups or among the six subgroups. The number of discontinuation due to the appearance of serious side effects was higher, but not statistically significant, in the LEF-anti-TNF-alpha group than in the MTX-anti-TNF-alpha group. Other adverse events that did not necessitate the discontinuation of therapy occurred much more frequently in patients treated with MTX than in those treated with LEF. Anti-TNF-alpha drugs can be used in combination not only with MTX, but also with LEF, with the same probability of achieving significant clinical improvement in RA patients and without a significantly greater risk of serious adverse events. In contrast, it seems that combination therapy with LEF-anti-TNF-alpha is more readily tolerated than combination therapy with MTX-anti-TNF-alpha.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Mcfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Atrhritis Rheum 41:1552–1563

    Article  CAS  Google Scholar 

  2. Lipsky PE et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602

    Article  CAS  PubMed  Google Scholar 

  3. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450

    Article  CAS  PubMed  Google Scholar 

  4. Klareskog L, van der Heijde D, de Jager JP, Kalden J, Malaise M, Gough A et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised trial. Lancet 363:675–681

    Article  CAS  PubMed  Google Scholar 

  5. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, doble-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37

    Article  CAS  PubMed  Google Scholar 

  6. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45

    Article  CAS  PubMed  Google Scholar 

  7. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: result of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571

    CAS  PubMed  Google Scholar 

  8. Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Seppänen O, Malmi T, Ylä-Kerttula T, Honkanen V (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 26:741–748

    Article  PubMed  Google Scholar 

  9. Zink A, Listing J, Kary S et al (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274–1279

    Article  CAS  PubMed  Google Scholar 

  10. O’Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A (2006) Etanercept in combination with Sulfasalazine, Hydroxychloroquine, or Gold in the treatment of rheumatoid arthritis. J Rheumatol 33:213–218

    PubMed  Google Scholar 

  11. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK et al (2006) Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 65:1357–1362

    Article  CAS  PubMed  Google Scholar 

  12. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG et al (2007) Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66:732–739

    Article  CAS  PubMed  Google Scholar 

  13. Patel SR, Bergen W, Kraemer A, Keenan G (2001) Efficacy and safety of remicade (infliximab) plus Arava (leflunomide) in rheumatoid arthritis. Arthritis Rheum 44(Suppl 9):S84

    Google Scholar 

  14. Kiely PDW, Johnson DM (2002) Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 41:631–637

    Article  CAS  PubMed  Google Scholar 

  15. Struppler C, Thies W, Schattenkirchner M, Kellner H (2002) Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis patients. Ann Rheum Dis 61:S388

    Google Scholar 

  16. Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A (2004) Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatology 22:328–330

    CAS  Google Scholar 

  17. Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR, Genovese M, Sundaramurthy S, Schiff M (2004) The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 51:228–232

    Article  CAS  PubMed  Google Scholar 

  18. Ortiz Garcia AM, Gonzales-Alvaro I, Rosello Pardo R, Carmona L, Fabregas Canales MD, Monteagudo Saez I (2004) Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis. Clin Exp Rheumatol 22:790

    CAS  PubMed  Google Scholar 

  19. Bingham SJ, Buch MH, Kerr MA et al (2004) Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 50(12):4072–4073

    Article  CAS  PubMed  Google Scholar 

  20. Flendrie M, Creemers MC, Welsing PM, van Riel PL (2005) The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology 44(4):472–478

    Article  CAS  PubMed  Google Scholar 

  21. Kalden JR, Antoni C, Alvaro-Garcia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS (2005) Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 32(8):1620–1631

    PubMed  Google Scholar 

  22. Cobo Ibanez T, Yehia Tayel M, Balsa Criado A, Hernandez Sanz A, Martin Mola E (2005) Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis. Rheumatology 44:1467–1468

    Article  CAS  PubMed  Google Scholar 

  23. Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL, Cantagrel A, Pavy S, Deslandre CJ, Debiais F, Combe B (2006) Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol 33(5):865–869

    CAS  PubMed  Google Scholar 

  24. Wislowska M, Jacubicz D (2007) Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int 27(7):641–647

    Article  CAS  PubMed  Google Scholar 

  25. Kalden JR, Nuslein HG, Wollenhaupt J, Burmester GR, Kruger K, Antoni C (2008) Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in open-label clinical trial. Clin Exp Rheumatol 26:834–840

    CAS  PubMed  Google Scholar 

  26. Finckh A, Dehler S, Gabay C, on behalf of the SCQM doctors (2009) The effectiveness of leflunomide as a co-therapy of tumor necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheu Dis 68:33–39

    Article  CAS  Google Scholar 

  27. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A (2009) Ann Rheu Dis 68:33–3

    Google Scholar 

  28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–334

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Rheumatology Unit, Azienda Ospedaliera Universitaria Senese, viale Bracci, 1, 53100, Siena, Italy

    Renato De Stefano, Elena Frati, Fernando Nargi, Caterina Baldi, Luana Menza, Mohammed Hammoud & Mauro Galeazzi

Authors
  1. Renato De Stefano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Frati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando Nargi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caterina Baldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luana Menza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammed Hammoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mauro Galeazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renato De Stefano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Stefano, R., Frati, E., Nargi, F. et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 29, 517–524 (2010). https://doi.org/10.1007/s10067-009-1349-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1349-y

Keywords

Search

Navigation